Abstract
We investigated the use of immunotherapy on the treatment of sodium arsenite toxicity. Female balb/c mice injected with arsanilic acid conjugated to a carrier protein (ovalbumin) were shown to produce antibodies (arsenic reactive serum, ARS) reactive with arsanilic acid and sodium arsenite. Serum was tested for anti-ARS antibodies using a solid phase radioimmunoassay. The antisera bound to ARS conjugated to the synthetic copolymer glutamic acid60 tyrosine30 when diluted as high as 1:4096. Following multiple injections of 100 μg of arsanilic acid - ovalbumin compound, mortality on injection with sodium arsenite 0.87 mg/kg i.p. one week later decreased to 0 deaths in 22 pretreated mice vs 9 deaths in 29 untreated mice (31% mortality; p < 005). No decrease in mortality was noted at higher challenges (1.15 mg/kg) of sodium arsenite. Antisera from pretreated mice was injected 0.1 cc i.p. into 12 week old female balb/c mice followed by an injection of sodium arsenite 0.87 mg/kg i.p. at 10 minutes. Again a protective effect was observed with 0 deaths in 18 mice vs eight deaths in 21 mice (38%; p < 005). Seventeen additional mice were given an injection of 0.87 mg/kg i.p. of sodium arsenite. After 30 minutes, all mice became symptomatic whereupon antisera 0.1 cc i.p. was given. The one day mortality (2/17, 12% was possibly lower than the combined control mortality (17/50, 34%; p < 0.07). There was no change in mortality noted when antisera was administered to mice acutely exposed to 5 mg/kg HgCl2.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 59-70 |
| Number of pages | 12 |
| Journal | Clinical Toxicology |
| Volume | 29 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 1991 |
Fingerprint
Keywords
- Arsanilic antibody
- Arsenic poisoning
- Arsenite
- Immunotherapy
- Mouse
- Sodium
ASJC Scopus subject areas
- Toxicology
Cite this
}
Immunotherapy in acute arsenic poisoning. / Leikin, Jerrold B.; Leikin, Robin G; Evans, Michael A.; Wiener, Stanley; Hryhorczuk, Daniel O.
In: Clinical Toxicology, Vol. 29, No. 1, 01.01.1991, p. 59-70.Research output: Contribution to journal › Article
TY - JOUR
T1 - Immunotherapy in acute arsenic poisoning
AU - Leikin, Jerrold B.
AU - Leikin, Robin G
AU - Evans, Michael A.
AU - Wiener, Stanley
AU - Hryhorczuk, Daniel O.
PY - 1991/1/1
Y1 - 1991/1/1
N2 - We investigated the use of immunotherapy on the treatment of sodium arsenite toxicity. Female balb/c mice injected with arsanilic acid conjugated to a carrier protein (ovalbumin) were shown to produce antibodies (arsenic reactive serum, ARS) reactive with arsanilic acid and sodium arsenite. Serum was tested for anti-ARS antibodies using a solid phase radioimmunoassay. The antisera bound to ARS conjugated to the synthetic copolymer glutamic acid60 tyrosine30 when diluted as high as 1:4096. Following multiple injections of 100 μg of arsanilic acid - ovalbumin compound, mortality on injection with sodium arsenite 0.87 mg/kg i.p. one week later decreased to 0 deaths in 22 pretreated mice vs 9 deaths in 29 untreated mice (31% mortality; p < 005). No decrease in mortality was noted at higher challenges (1.15 mg/kg) of sodium arsenite. Antisera from pretreated mice was injected 0.1 cc i.p. into 12 week old female balb/c mice followed by an injection of sodium arsenite 0.87 mg/kg i.p. at 10 minutes. Again a protective effect was observed with 0 deaths in 18 mice vs eight deaths in 21 mice (38%; p < 005). Seventeen additional mice were given an injection of 0.87 mg/kg i.p. of sodium arsenite. After 30 minutes, all mice became symptomatic whereupon antisera 0.1 cc i.p. was given. The one day mortality (2/17, 12% was possibly lower than the combined control mortality (17/50, 34%; p < 0.07). There was no change in mortality noted when antisera was administered to mice acutely exposed to 5 mg/kg HgCl2.
AB - We investigated the use of immunotherapy on the treatment of sodium arsenite toxicity. Female balb/c mice injected with arsanilic acid conjugated to a carrier protein (ovalbumin) were shown to produce antibodies (arsenic reactive serum, ARS) reactive with arsanilic acid and sodium arsenite. Serum was tested for anti-ARS antibodies using a solid phase radioimmunoassay. The antisera bound to ARS conjugated to the synthetic copolymer glutamic acid60 tyrosine30 when diluted as high as 1:4096. Following multiple injections of 100 μg of arsanilic acid - ovalbumin compound, mortality on injection with sodium arsenite 0.87 mg/kg i.p. one week later decreased to 0 deaths in 22 pretreated mice vs 9 deaths in 29 untreated mice (31% mortality; p < 005). No decrease in mortality was noted at higher challenges (1.15 mg/kg) of sodium arsenite. Antisera from pretreated mice was injected 0.1 cc i.p. into 12 week old female balb/c mice followed by an injection of sodium arsenite 0.87 mg/kg i.p. at 10 minutes. Again a protective effect was observed with 0 deaths in 18 mice vs eight deaths in 21 mice (38%; p < 005). Seventeen additional mice were given an injection of 0.87 mg/kg i.p. of sodium arsenite. After 30 minutes, all mice became symptomatic whereupon antisera 0.1 cc i.p. was given. The one day mortality (2/17, 12% was possibly lower than the combined control mortality (17/50, 34%; p < 0.07). There was no change in mortality noted when antisera was administered to mice acutely exposed to 5 mg/kg HgCl2.
KW - Arsanilic antibody
KW - Arsenic poisoning
KW - Arsenite
KW - Immunotherapy
KW - Mouse
KW - Sodium
UR - http://www.scopus.com/inward/record.url?scp=0026013303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026013303&partnerID=8YFLogxK
U2 - 10.3109/15563659109038598
DO - 10.3109/15563659109038598
M3 - Article
VL - 29
SP - 59
EP - 70
JO - Clinical Toxicology
JF - Clinical Toxicology
SN - 1556-3650
IS - 1
ER -